Pharmaceuticals & Therapeutics

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Zevra Therapeutics' new data for MIPLYFFA in infants with NPC is more than a medical update; it's a key commercial milestone to widen its market.

A new partnership between AGEPHA Pharma and Close-Up Intl reveals how AI is not just a buzzword, but a critical tool for getting vital medicines to patients.

An FDA fast-track for a devastating brain disease drug is a beacon of hope for patients and a major validation of Alphabet's long-term biotech strategy.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

A new, fast-acting neurotoxin with a two-week lifespan just hit the market. Allergan's Boey® aims to capture hesitant consumers with a low-commitment 'trial run'.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

Insmed recruits J&J and Novartis veteran Samuele Butera to execute the multi-billion-dollar launch of BRINSUPRI and expand its respiratory franchise.

A new survey reveals the crippling cost of insulin, forcing millions to choose between medicine and groceries. A bipartisan bill may offer a lifeline.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

The European Commission has approved MAVIRET for acute Hepatitis C, a move set to streamline patient care and accelerate progress against a silent epidemic.

AbbVie's blockbuster SKYRIZI wins European approval for pediatric psoriasis, unlocking a new market and offering a new standard of care to young patients.

Ottawa's quiet $892K investment in a Vancouver biotech firm is more than a grant; it's a calculated move to secure Canada's food supply from a post-antibiotic crisis.

A decade of new science has prompted the FDA to overhaul testosterone therapy rules, erasing old fears and unlocking a multi-billion dollar market for aging men.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

Praxis Precision Medicines' elsunersen earns Breakthrough Therapy status, signaling a major step toward the first disease-modifying treatment for SCN2A-DEE.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

Merck's positive Phase 3 results for tulisokibart signal a new era for UC care, targeting both fibrosis and inflammation in a potential first-in-class win.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.